Respiratory Syncytial Virus Bronchiolitis in Congenital Diaphragmatic Hernia: A systematic review of prevalence rates and Palivizumab prophylaxis

2021 ◽  
Author(s):  
Leonie Lewis ◽  
Ian Sinha ◽  
Paul D Losty
Keyword(s):  
Systematic Review ◽  
Respiratory Syncytial Virus ◽  
Congenital Diaphragmatic Hernia ◽  
Diaphragmatic Hernia ◽  
Prevalence Rates ◽  
Respiratory Syncytial Virus Bronchiolitis ◽  
Syncytial Virus

scholarly journals Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017

2018 ◽  
Vol 69 (6) ◽  
pp. 980-986 ◽  
Author(s):  
Doyoung Kim ◽  
Mahwesh Saleem ◽  
Bosco Paes ◽  
Ian Mitchell ◽  
Krista L Lanctôt
Keyword(s):  
Respiratory Syncytial Virus ◽  
Congenital Diaphragmatic Hernia ◽  
Diaphragmatic Hernia ◽  
Respiratory Illness ◽  
Evaluation Study ◽  
Cox Proportional Hazards ◽  
Respiratory Morbidity ◽  
Increased Risk ◽  
Syncytial Virus ◽  
Tract Infections

Abstract Background Infants with congenital diaphragmatic hernia (CDH) are at an increased risk of respiratory morbidity from recurrent respiratory tract infections including those from respiratory syncytial virus (RSV). Prospective studies on RSV prophylaxis in CDH infants are limited. We determined the risk of respiratory illness– and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SIs) and those without increased risk (NR). Methods The prospective Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab (CARESS) registry was searched for infants who received palivizumab during 12 RSV seasons (2005–2017) in Canada. Cox proportional hazards analyses were conducted to compare RIH and RSVH risks across the groups adjusted for potential confounders. Results In total, 21 107 infants (201 CDH, 389 NR, and 20 517 SI) were included. RIH incidences were 10.0% (CDH), 2.1% (NR), and 6.2% (SI). CDH patients had a significantly higher RIH hazard compared with NR (hazard ratio [HR], 3.6 [95% confidence interval {CI}, 1.5–8.8]; P = .005) but not SI (HR, 1.2 [95% CI, .8–2.0]; P = .379). RSVH incidences were 0.6%, 0.3%, and 1.5% for CDH, NR, and SI, respectively. RSVH risk was similar across groups (SI: HR, 0.0, P = .922; NR: HR, 0.0, P = .934). Conclusions CDH infants had a 3-fold increased risk of RIH compared to NR but not SI infants. RSVH risk was similar with low RSVH incidences across all groups, implying that CDH infants may benefit from palivizumab during the RSV season, similar to other high-risk groups. Clinical Trials Registration NCT00420966.

scholarly journals Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia

2018 ◽  
Vol 59 (2) ◽  
pp. 184-188 ◽  
Author(s):  
Bernhard Resch ◽  
Krisztina Liziczai ◽  
Friedrich Reiterer ◽  
Thomas Freidl ◽  
Michaela Haim ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Congenital Diaphragmatic Hernia ◽  
Diaphragmatic Hernia ◽  
Syncytial Virus

Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia

2008 ◽  
Vol 50 (4) ◽  
pp. 459-463 ◽  
Author(s):  
Kouji Masumoto ◽  
Kouji Nagata ◽  
Toru Uesugi ◽  
Tomomi Yamada ◽  
Tadamune Kinjo ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Congenital Diaphragmatic Hernia ◽  
Diaphragmatic Hernia ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document